Efficacy and tolerability of atorvastatin as add on therapy in the treatment of chronic stable (moderate-severe) asthma for a duration of 8 weeks


  • Sunil Nettath Department of Pharmacology, Karuna Medical College, Palakkad, Kerala, India


Atorvastatin, Chronic stable asthma, Immunomodulatory, Inflammatory, Pleiotropism


Atorvastatin, lipid lowering agent has a well established safety profile both in the primary and secondary prevention of cardiovascular diseases. Statins role as anti inflammatory and immunomodulatory effects what is called pleiotropism of statins is being explored and tried in the treatment of various diseases like asthma. Here this study highlights the efficacy and tolerability of atorvastatin as an add on therapy in the treatment of chronic stable asthma .this study concludes the statistical significance of atorvastatin 20mg dose as an adjuvant in chronic stable asthma.


Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59(5):469-78.

Bradley J. Undem. Goodman and Gilman’s The Pharmacological basis of therapeutics, 11th edition, Pharmacotherapy of asthma, chapter 27;page 717.

Hajime Takizawa, Novel Strategies for the Treatment of Asthma Recent Patents on Inflammation & Allergy Drug Discovery 2007, 1, 13-19

ER. McFadden, Jr., Harrisons principles of internal medicine – 16th edition asthma, chapter 252; page 1508-1515.

Stacey E. Alexeeff, Augusto A. Litonjua, David Sparrow, Pantel S. Vokonas and Joel Schwartz, V A Normative study: American Journal of Respiratory and Critical Care Medicine 2007;176:742-747.

Dunnil MS. The pathology of asthma, with special reference to changes in the bronchial mucosa.J Clin Pathol 1960;13:27-33.

Curschmann H. Ueber bronchiolitis exsudative und ihr Verhaltniss zum asthma nervosum. Dtsch Arch Klin Med 1882;32:1-34 [in German].

Hamid Q, Song Y,Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100:44-51.

Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to large airways. J Allergy Clin Immunol 1998; 101:386-90.

Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505-10.

Taha RA, Minshall EM, Miotto D, et al. Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and non asthmatic individuals. J Allergy Clin Immunol 1999;103:476-83.

Schulman ES, Adkinson NFJ, Newball HH. Cyclooxygenase metabolites in human lung anaphylaxis: airway vs parenchyma. J Appl Physiol 1982;53:589-95.

Yoshihiko Chiba, Junko Arima, Hiroyasu Sakai, and Miwa Misawa . Am J Physiol Lung Cell Mol Physiol, 2008, 294:L705-L713.

V. Søyseth, P.H. Brekke, P. Smith, T. Omland. Eur Respir J 2007; 29:279-283.

A. I. Blamoun, G. N. Batty, V. A. DeBari, A. O. Rashid, M. Sheikh, M. A. Khan Int J Clin Pract, September 2008, 62, 9, 1373–1378.




How to Cite

Nettath, S. (2017). Efficacy and tolerability of atorvastatin as add on therapy in the treatment of chronic stable (moderate-severe) asthma for a duration of 8 weeks. International Journal of Basic & Clinical Pharmacology, 2(6), 792–798. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1369



Original Research Articles